Omics analyses provide insights to CART cell therapy resistance

Abstract

Chimeric antigen receptor T (CART) cell therapy has revolutionized the treatment of relapsed/refractory B cell malignancies in recent years. Despite high initial response rates, durable response rates are low, and CART cell efficacy in solid tumors is very modest. Additionally, the overall success of CART cell therapy is limited by toxicities such as cytokine release syndrome and neurotoxicity. Decades of advancement in genome sequencing technology and bioinformatics have given us a better understanding of how cancer develops and evolves following treatments. This has resulted in a better understanding of patient response to cancer treatment on a molecular level. Resistance to CART cell therapy can be mediated by the cancer cells, the tumor microenvironment, or the patient’s T cells. In this review, we will outline lessons learned from multi-omics studies (1) to identify biomarkers of response or toxicity to CART cell therapy or (2) to develop biomarker-guided therapeutic interventions to overcome these limitations.

Keywords

Chimeric antigen receptor T cell (CART) / tumor microenvironment (TME) / omics / genetics / sequencing

References

[1] SieglerEL.Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies.Front Immunol2020;11:1973 PMCID:PMC7485001

[2] McCuneJS.Rapid advances in immunotherapy to treat cancer.Clin Pharmacol Ther2018;103:540-4

[3] MaudeSL,BuechnerJ.Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.N Engl J Med2018;378:439-48 PMCID:PMC5996391

[4] SchusterSJ,TamCS.JULIET InvestigatorsTisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.N Engl J Med2019;380:45-56

[5] GrossG,EshharZ.Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.Proc Natl Acad Sci U S A1989;86:10024-8 PMCID:PMC298636

[6] EshharZ,GrossG.Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.Proc Natl Acad Sci U S A1993;90:720-4 PMCID:PMC45737

[7] MausMV,PorterDL.Antibody-modified T cells: CARs take the front seat for hematologic malignancies.Blood2014;123:2625-35 PMCID:PMC3999751

[8] ParkJH,GonenM.Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.N Engl J Med2018;378:449-59 PMCID:PMC6637939

[9] PalumboA,DelforgeM.MM-015 InvestigatorsContinuous lenalidomide treatment for newly diagnosed multiple myeloma.N Engl J Med2012;366:1759-69

[10] RajeN,LinY.Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma.N Engl J Med2019;380:1726-37

[11] XuX,LiangX.Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies.Front Immunol2019;10:2664 PMCID:PMC6863137

[12] MaS,WangX.Current progress in CAR-T cell therapy for solid tumors.Int J Biol Sci2019;15:2548-60 PMCID:PMC6854376

[13] BeattyGL,MausMV.Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.Cancer Immunol Res2014;2:112-20 PMCID:PMC3932715

[14] BrownCE,StarrR.Regression of glioblastoma after chimeric antigen receptor T-cell therapy.N Engl J Med2016;375:2561-9 PMCID:PMC5390684

[15] JohnsonLA,OhkuriT.Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.Sci Transl Med2015;7:275ra22 PMCID:PMC4467166

[16] WunderlichV.Early references to the mutational origin of cancer.Int J Epidemiol2007;36:246-7

[17] DulbeccoR.A turning point in cancer research: sequencing the human genome.Science1986;231:1055-6

[18] YngvadottirB,JinH.The promise and reality of personal genomics.Genome Biol2009;10:237 PMCID:PMC2768970

[19] AbecasisGR,AutonA.1000 Genomes Project ConsortiumA map of human genome variation from population-scale sequencing.Nature2010;467:1061-73 PMCID:PMC3042601

[20] HanahanD.Hallmarks of cancer: the next generation.Cell2011;144:646-74

[21] FraiettaJA,OrlandoEJ.Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.Nat Med2018;24:563-71 PMCID:PMC6117613

[22] DengQ,Puebla-OsorioN.Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas.Nat Med2020;26:1878-87

[23] WrightGW,PhelanJD.A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications.Cancer Cell2020;37:551-568.e14

[24] SheihA,HanafiLA.Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy.Nat Commun2020;11:219 PMCID:PMC6954177

[25] Manriquez-RomanC,KenderianSS.CRISPR takes the front seat in CART-cell development.BioDrugs2021;35:113-24

[26] WangW,CattauB.Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and single-cell levels.Proc Natl Acad Sci U S A2020;117:5442-52 PMCID:PMC7071901

[27] Gomes-SilvaD,SrinivasanM.Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent.Cell Rep2017;21:17-26 PMCID:PMC5645034

[28] LongAH,ShernJF.4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.Nat Med2015;21:581-90 PMCID:PMC4458184

[29] SternerRM,CoxMJ.GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.Blood2019;133:697-709 PMCID:PMC6376281

[30] ParkerKR,PerkeyE.Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies.Cell2020;183:126-142.e17 PMCID:PMC7640763

[31] CoxMJ,SakemuraR.Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.Mol Ther2021;29:1529-40 PMCID:PMC8058445

[32] SakemuraR,HansenMJ.Targeting cancer associated fibroblasts in the bone marrow prevents resistance to chimeric antigen receptor T cell therapy in multiple myeloma.Blood2019;134:865

[33] CassettaL,SimsAH.Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets.Cancer Cell2019;35:588-602.e10 PMCID:PMC6472943

[34] JainMD,StaedtkeV.The lymphoma tumor microenvironment influences toxicity after CD19 CAR T cell therapy.Blood2019;134:4105

[35] JainMD,AtkinsR.Tumor inflammation and myeloid derived suppressor cells reduce the efficacy of CD19 CAR T cell therapy in lymphoma.Blood2019;134:2885

[36] LeeHW,LeeHO.Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient.Genome Med2020;12:47 PMCID:PMC7251908

[37] CooperZA,JunejaVR.BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes.Oncoimmunology2013;2:e26615 PMCID:PMC3827093

[38] MarabelleA,LopezJ.Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol2020;21:1353-65

[39] MajznerRG.Tumor antigen escape from CAR T-cell therapy.Cancer Discov2018;8:1219-26

[40] MaudeSL,ShawPA.Chimeric antigen receptor T cells for sustained remissions in leukemia.N Engl J Med2014;371:1507-17 PMCID:PMC4267531

[41] SotilloE,BlackKL.Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy.Cancer Discov2015;5:1282-95 PMCID:PMC4670800

[42] BarashY,González-VallinasJ.AVISPA: a web tool for the prediction and analysis of alternative splicing.Genome Biol2013;14:R114 PMCID:PMC4014802

[43] SinghN,ShestovaO.impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction.Cancer Discov2020;10:552-67 PMCID:PMC7416790